ArticleJournal of translational medicine2026
Tissue-resident Limosilactobacillus reuteri modulates intratumoral arachidonic acid metabolism to enhance CD8
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTissue-resident bacteria have emerged as modulators of host responses to tumor immunotherapy. However, the immunological and metabolic mechanisms by which tissue-resident microbiota influence immune checkpoint blockade in colorectal cancer (CRC) remain incompletely defined.
methodsWe profiled the microbial composition of colorectal tissues from CRC patients and identified differentially enriched taxa between tumors and adjacent non-tumor tissues(NTs). By focusing on tissue-resident bacteria within the colorectal tumor microenvironment, immunocompetent mouse models were used to evaluate the impact of Limosilactobacillus reuteri (enriched in NTs) on tumor growth, survival, and anti-PD1 efficacy. Single-cell RNA sequencing combined with flow cytometric analysis was applied to characterize the phenotypic features of CD8⁺ T cells following anti-PD1 treatment with or without L.reuteri. Untargeted metabolomics combined with flow cytometry was conducted to investigate the association between tissue-resident L.reuteri and intratumoral lipid metabolic remodeling.
resultsL.reuteri administration significantly enhanced the efficacy of anti-PD1 therapy, reduced tumor burden (MC38: 95% CI −755.20 to −210.90 mm3, P < 0.0001; CT26: 95% CI −558.30 to −340.70 mm3, P < 0.0001), and prolonged survival (MC38: log-rank P < 0.01; CT26: log-rank P < 0.01) across multiple mouse models. Mechanistically, L.reuteri reduced CD8⁺ T-cell exhaustion and strengthened effector function. Untargeted metabolomic profiling revealed that L.reuteri remodeled intratumoral lipid metabolism, reflected by a moderate increase in arachidonic acid (AA) levels. These metabolic changes promoted CD8⁺ T-cell activation and cytotoxicity within the TME.
conclusionOur study demonstrated that tissue-resident L.reuteri enhances anti-PD1 efficacy in CRC by alleviating CD8⁺ T cell exhaustion through reprogramming intratumoral lipid metabolism, highlighting the therapeutic potential of microbiota-based immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.